PharmEasy-Owned Thyrocare’s Q3 Profit Jumps 29% To INR 19 Cr

Share via:


SUMMARY

Sequentially, profit declined 28.27% from INR 26.42 Cr

Operating revenue grew 23.38% to INR 165.92 Cr during the quarter under review from INR 134.47 Cr in Q3 FY24

Total expenses grew 20.52% to INR 141.85 Cr during the quarter under review from INR 117.69 Cr in Q3 FY24

PharmEasy-owned diagnostics platform Thyrocare’s consolidated net profit zoomed 28.56% to INR 18.95 Cr in the third quarter of the financial year 2024-25 (FY25) from INR 14.74 Cr in the year-ago quarter.

Sequentially, profit declined 28.27% from INR…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

PharmEasy-Owned Thyrocare’s Q3 Profit Jumps 29% To INR 19 Cr


SUMMARY

Sequentially, profit declined 28.27% from INR 26.42 Cr

Operating revenue grew 23.38% to INR 165.92 Cr during the quarter under review from INR 134.47 Cr in Q3 FY24

Total expenses grew 20.52% to INR 141.85 Cr during the quarter under review from INR 117.69 Cr in Q3 FY24

PharmEasy-owned diagnostics platform Thyrocare’s consolidated net profit zoomed 28.56% to INR 18.95 Cr in the third quarter of the financial year 2024-25 (FY25) from INR 14.74 Cr in the year-ago quarter.

Sequentially, profit declined 28.27% from INR…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Aspirations, Data & Innovations:The New Consumer Playbook For D2C

SUMMARY To decode the changing landscape, Inc42 and Cashfree...

World Finance Council Announces WFC Fintech 2025 Dubai: Redefining...

The World Finance Council proudly unveils the highly anticipated...

Infosys expands its campus in Hyderabad, to create 17,000...

Infosys Ltd, India's second-largest IT services firm and...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!